<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446641</url>
  </required_header>
  <id_info>
    <org_study_id>ARCC</org_study_id>
    <nct_id>NCT00446641</nct_id>
  </id_info>
  <brief_title>Overcome Biochemical Aspirin Resistance Through Cilostazol Combination</brief_title>
  <acronym>ARCC</acronym>
  <official_title>Phase 4 Study of Additional Cilostazol for Overcoming Biochemical Aspirin Resistance in the Chronic Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will recruit 316 ischemic stroke patients taking aspirin.

      They will be randomly assigned into cilostazol group or placebo group. Every patients will
      take 200mg of cilostazol a day or placebo for 1 month.

      The primary outcome variable of this study is rate of biochemical aspirin resistance on the
      Ultra Rapid Platelet Function Assay-ASA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Goal] To reveal the effect and safety of additional cilostazol for overcoming biochemical
      aspirin resistance.

      [Trial Design] Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial

      [Participants] Ischemic stroke patients taking aspirin

      [Methods]

        -  Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial

        -  Investigational product: Cilostazol 200mg (100mg twice per day)

        -  Concomitant medication: Aspirin 100 mg per day

        -  Medication Duration: 1 month

      [Outcome Variables]

      Primary Outcome Variable:

      • the proportion of patients with aspirin reaction units (ARUs) values ≥550 on the Ultra
      Rapid Platelet Function Assay-ASA

      Secondary outcome variables:

        -  the proportion of patients with ARUs values ≥500 on the Ultra Rapid Platelet Function
           Assay-ASA

        -  ARUs values

        -  Bleeding time (BT)

        -  Fatal or major bleeding complications

        -  Any bleeding complications
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aspirin Resistance (ARU ≥ 550)</measure>
    <time_frame>4 weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aspirin Resistance (ARU ≥ 500)</measure>
    <time_frame>4 weeks after reatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Time (BT)</measure>
    <time_frame>4 weeks after reatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatal or Major Bleeding Complications;</measure>
    <time_frame>events ocurred during study medication after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Bleeding Complications</measure>
    <time_frame>events ocurred during study medication after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of Post-treatment ARU and Baseline ARU</measure>
    <time_frame>baseline ARU measured at the randomization and post-treatment ARU measured at the 4weeks treatment with study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment ARU</measure>
    <time_frame>after 4 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>1 Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg of Cilostazol twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo to cilostazol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>cilostazol 100mg twice a day for 4 weeks</description>
    <arm_group_label>1 Cilostazol</arm_group_label>
    <other_name>pletaal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 1 tablet twice a day matching for cilostazol</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>matching placebo of cilostazol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic cerebral infarction documented on MRI or CT

          -  More than 35 years of age

          -  Patients taking aspirin 100mg a day for 2 weeks or more before randomization

        Exclusion Criteria:

          -  Patients taking any antiplatelets other than aspirin within 2 weeks before
             randomization

          -  Patients taking any anticoagulants within 2 weeks before randomization

          -  Patients taking thrombolytic therapy within 2 weeks before randomization

          -  Patients taking any NSAIDs within 2 weeks before randomization

          -  Patients who need to take NSAIDs regularly (e.g. rheumatic arthritis).

          -  Bleeding diathesis

          -  Chronic liver disease (ALT &gt; 100 or AST &gt; 100) or chronic renal disease (creatinine &gt;
             3.0mg/dl)

          -  Anemia (hemoglobin &lt; 10mg/dl) or thrombocytopenia (platelet count less than
             100,000/mm3)

          -  Pregnant or lactating patients

          -  Patients scheduled for angioplasty or revascularization procedures within 4 weeks

          -  Patients scheduled for any surgery or invasive procedures within 4 weeks

          -  Patients having acute coronary syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun U Kwon, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center, Univsersity of Ulsan, Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jae-Kwan Cha</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejon</city>
        <zip>302-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital, Hallym University</name>
      <address>
        <city>Seoul</city>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2007</study_first_submitted>
  <study_first_submitted_qc>March 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2007</study_first_posted>
  <results_first_submitted>January 22, 2009</results_first_submitted>
  <results_first_submitted_qc>December 10, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2010</results_first_posted>
  <last_update_submitted>December 10, 2009</last_update_submitted>
  <last_update_submitted_qc>December 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sun U. Kwon</name_title>
    <organization>Asan Medical Center</organization>
  </responsible_party>
  <keyword>Infarction, Cerebral</keyword>
  <keyword>Cilostazol</keyword>
  <keyword>Aspirin Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>244 patients with subacute or chronic ischemic stroke were recruited from outpatient clinics of 5 comprehensive stroke centers of Korea</recruitment_details>
      <pre_assignment_details>Patients with aspirin therapy were recruited due to subacute or chronic ischemic stroke.
The patients should have taken aspirin 100mg per day at least 2 weeks before randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cilostazol</title>
          <description>Cilostazol 100mg twice per day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matching placebo to cilostazol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>poor compliance</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cilostazol</title>
          <description>Cilostazol 100mg twice per day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>matching placebo to cilostazol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="119"/>
            <count group_id="B3" value="244"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.24" spread="10.198"/>
                    <measurement group_id="B2" value="62.83" spread="9.963"/>
                    <measurement group_id="B3" value="62.02" spread="10.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aspirin Resistance (ARU ≥ 550)</title>
        <description>The number of patients with aspirin reaction units (ARUs) values ≥ 550 on the Ultra Rapid Platelet Function Assay-ASA among the recruited patients</description>
        <time_frame>4 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol 100mg twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo to cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Aspirin Resistance (ARU ≥ 550)</title>
          <description>The number of patients with aspirin reaction units (ARUs) values ≥ 550 on the Ultra Rapid Platelet Function Assay-ASA among the recruited patients</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We assumed that the prevalence of AR would be 12 % among ischemic stroke patients who were treated with aspirin 100 per day. The prevalence could be reduced to 4% with additional cilostazol therapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.654</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspirin Resistance (ARU ≥ 500)</title>
        <description>The number of participants with ARUs values ≥500 on the Ultra Rapid Platelet Function Assay-ASA; ARUs values</description>
        <time_frame>4 weeks after reatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol 100mg twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo to cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Aspirin Resistance (ARU ≥ 500)</title>
          <description>The number of participants with ARUs values ≥500 on the Ultra Rapid Platelet Function Assay-ASA; ARUs values</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Time (BT)</title>
        <description>for evaluation of the extent of the bleeding time prolongation by additional cilostazol</description>
        <time_frame>4 weeks after reatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol 100mg twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo to cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Time (BT)</title>
          <description>for evaluation of the extent of the bleeding time prolongation by additional cilostazol</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="38.5"/>
                    <measurement group_id="O2" value="106" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatal or Major Bleeding Complications;</title>
        <description>Fatal or life-threatening bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood</description>
        <time_frame>events ocurred during study medication after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol 100mg twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo to cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Fatal or Major Bleeding Complications;</title>
          <description>Fatal or life-threatening bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Bleeding Complications</title>
        <description>any bleeding events causing medical attention</description>
        <time_frame>events ocurred during study medication after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol 100mg twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo to cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Any Bleeding Complications</title>
          <description>any bleeding events causing medical attention</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference of Post-treatment ARU and Baseline ARU</title>
        <description>summation of change of ARU (posttreatment ARU - baseline ARU) of individual patients</description>
        <time_frame>baseline ARU measured at the randomization and post-treatment ARU measured at the 4weeks treatment with study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol 100mg twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo to cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Difference of Post-treatment ARU and Baseline ARU</title>
          <description>summation of change of ARU (posttreatment ARU - baseline ARU) of individual patients</description>
          <units>change of ARU measured</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="77.6"/>
                    <measurement group_id="O2" value="12.1" spread="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment ARU</title>
        <description>mean of ARU value of individual participants after 4 weeks treatment</description>
        <time_frame>after 4 weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol 100mg twice per day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo to cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment ARU</title>
          <description>mean of ARU value of individual participants after 4 weeks treatment</description>
          <units>ARU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454.8" spread="52.8"/>
                    <measurement group_id="O2" value="473.6" spread="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cilostazol</title>
          <description>Cilostazol 100mg twice per day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>matching placebo to cilostazol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Sun U. Kwon</name_or_title>
      <organization>Asan Medical Center, University of Ulsan College of Medicine</organization>
      <phone>82-2-3010-3960</phone>
      <email>sukwon@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

